drugset
drugset / Press release

The IND application for Project GS101 was accepted by the CDE

2025-11-01 · Jiangsu Genscend Biopharmaceutical Co., Ltd · original genscend.com ↗

aganirsen · regulatory

On November 7, 2025, Jiangsu Genscend Biopharma Co., Ltd received the Acceptance Notice issued by the National Medical Products Administration (NMPA). The IND application for a Dupixent biosimilar (Project code:GS101) has been accepted, with acceptance number: CXSL2500955.

The release as fetched from its publisher. genscend.com ↗